Prostate cancer is common, so detecting it sounds like a no-brainer. But in recent years, screening recommendations have changed several times.

According to A. Mustajeeb Haseeb, M.D., a board-certified medical oncologist at California Cancer Associates for Research and Excellence (cCARE), prostate cancer accounts for 27 percent of cancer diagnoses—second-most among men in the United States. It's most common in men ages 65 and older, with 6 in 10 cases occurring in this age group.

Despite the prevalence of the disease, a debate has developed over the benefits of prostate cancer screening versus the risks, which include overdiagnosis and treating the disease when a wait-and-see approach might be more practical.

What do clinicians think?

A bit of background

The prostate-specific antigen (PSA) test and digital rectal examination (DRE) are still used to aid in the detection of prostate cancer in men ages 50 and older, but prior to 2012, they were a more highly rated part of the screening process, especially the PSA